(-)-alpha-Bisabolol; alpha-Bisabolol; Bisabolol; Kamillosan; UNII-24WE03BX2T; alpha-(-)-Bisabolol; 24WE03BX2T; (2S)-6-methyl-2-[(1S)-4-methylcyclohex-3-en-1-yl]hept-5-en-2-ol; Levomenolum; Kamilosan; 1-alpha-Bisabolol; Levomenol [INN]; alpha-Bisabolol, L-; alpha-Bisabolol (-)-form; Levomenolum [INN-Latin]; Bisbalol; CCRIS 9081; EINECS 245-423-3; l-.alpha.-Bisabolol; .alpha.-Bisabolol, L-; .alpha.-(-)-Bisabolol; (-)--BISABOLOL; ALPHA-(-)BISABOLOL; DSSTox_CID_22094; DSSTox_RID_79924; DSSTox_GSID_42094; SCHEMBL24989; .alpha.-Bisabolol (-)-form; ((-))-6-Methyl-2-(4-methyl-3-cyclohexen-1-yl)-5-hepten-2-ol; CHEMBL1096927; DTXSID4042094; (-)-6-Methyl-2-(4-methyl-3-cyclohexen-1-yl)-5-hepten-2-ol; HY-N6967; ZINC1849759; [S-(R*,R*)]-.alpha.-Bisabolol; Tox21_301375; 5-Hepten-2-ol, 6-methyl-2-(4-methyl-3-cyclohexen-1-yl)-, (-)-; BDBM50382730; MFCD03412455; DB13153; LMPR0103060001; (-)-alpha-Bisabolol, >=93% (GC); (-)-Alpha-bisabolol(-)-alpha-bisabolol; NCGC00255987-01; (-)-alpha-Bisabolol, analytical standard; CS-0028206; Alpha-Bisabolol 1000 microg/mL in Isopropanol; C09621; Q179896; J-014978; UNII-36HQN158VC component RGZSQWQPBWRIAQ-CABCVRRESA-N; (-)-alpha-Bisabolol, primary pharmaceutical reference standard; Levomenol, United States Pharmacopeia (USP) Reference Standard; (S)-6-Methyl-2-((S)-4-methylcyclohex-3-en-1-yl)hept-5-en-2-ol; 6-Methyl-2-(4-methyl-3-cyclohexen-1-yl)-5-hepten-2-ol, (-)-; 3-Cyclohexene-1-methanol, a,4-dimethyl-a-(4-methyl-3-pentenyl)-,(aS,1S)-